Skip to main content

Advertisement

SpringerLink
Log in

Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues

  • Letter to the Editor
  • Published:
Hepatology International Aims and scope Submit manuscript

The Original Article was published on 16 October 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Liu J, Wang P, Shang L, Zhang Z, Tian Y, Chen X, et al. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis. Hepatol Int 2023. Online ahead of print

  2. Guo P, Pi X, Gao F, Li Q, Li D, Feng W, et al. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study. Front Oncol. 2022;12: 945915

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al. Response evaluation criteria in cancer of the liver (RECICL) proposed by the liver cancer study group of Japan (2009 revised version). Hepatol Res. 2010;40(7):686–692

    Article  PubMed  Google Scholar 

  4. Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, et al. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study. BJS Open. 2022;6(5):zrac114

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhu XD, Huang C, Shen YH, Xu B, Ge NL, Ji Y, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-PD-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 2023;30(5):2782–2790

    Article  PubMed  Google Scholar 

  6. Wu JY, Zhang ZB, Zhou JY, Ke JP, Bai YN, Chen YF, et al. Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study. Liver Cancer. 2023;12(3):229–237

    Article  CAS  PubMed  Google Scholar 

  7. Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L, et al. Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. 2022;13: 848387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The comment does not receive any funding.

Author information

Authors and Affiliations

  1. Department of Vascular Surgery, Nantong First People’s Hospital, The Second Affiliated Hospital of Nantong University, 666 Shengli Road, Chongchuan District, Nantong, 226014, Jiangsu Province, China

    Shiye Yang, Huoqi Liang, Xing Li, Jiayi Qian & Zhibing Ming

Authors
  1. Shiye Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huoqi Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiayi Qian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhibing Ming
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SY: study design and writing. ZM: critical review and study supervision.

Corresponding author

Correspondence to Zhibing Ming.

Ethics declarations

Conflict of interest

The authors who participate in this comment have no conflicts of interest to declare.

Ethical approval

Not applicable for this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, S., Liang, H., Li, X. et al. Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues. Hepatol Int (2024). https://doi.org/10.1007/s12072-024-10651-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12072-024-10651-z

Search

Navigation